Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity

被引:607
作者
Smyth, MJ [1 ]
Dunn, GP
Schreiber, RD
机构
[1] Peter MacCallum Canc Ctr, Canc Immunol Program, E Melbourn, Vic 3002, Australia
[2] Washington Univ, Ctr Immunol, Dept Pathol & Immunol, St Louis, MO 63130 USA
来源
ADVANCES IN IMMUNOLOGY, VOL 90: CANCER IMMUNOTHERAPY | 2006年 / 90卷
关键词
D O I
10.1016/S0065-2776(06)90001-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cellular transformation and tumor development result from an accumulation Of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate (is to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, toe discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action Of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.
引用
收藏
页码:1 / 50
页数:50
相关论文
共 279 条
  • [61] ENHANCED IN-VIVO GROWTH AND RESISTANCE TO REJECTION OF TUMOR-CELLS EXPRESSING DOMINANT-NEGATIVE IFN-GAMMA RECEPTORS
    DIGHE, AS
    RICHARDS, E
    OLD, LJ
    SCHREIBER, RD
    [J]. IMMUNITY, 1994, 1 (06) : 447 - 456
  • [62] A critical function for type I interferons in cancer immunoediting
    Dunn, GP
    Bruce, AT
    Sheehan, KCF
    Shankaran, V
    Uppaluri, R
    Bui, JD
    Diamond, MS
    Koebel, CM
    Arthur, C
    White, JM
    Schreiber, RD
    [J]. NATURE IMMUNOLOGY, 2005, 6 (07) : 722 - 729
  • [63] IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression
    Dunn, GP
    Sheehan, KCF
    Old, LJ
    Schreiber, RD
    [J]. CANCER RESEARCH, 2005, 65 (08) : 3447 - 3453
  • [64] The immunobiology of cancer immunosurveillance and immunoediting
    Dunn, GP
    Old, LJ
    Schreiber, RD
    [J]. IMMUNITY, 2004, 21 (02) : 137 - 148
  • [65] Cancer immunoediting: from immunosurveillance to tumor escape
    Dunn, GP
    Bruce, AT
    Ikeda, H
    Old, LJ
    Schreiber, RD
    [J]. NATURE IMMUNOLOGY, 2002, 3 (11) : 991 - 998
  • [66] The three Es of cancer immunoediting
    Dunn, GP
    Old, LJ
    Schreiber, RD
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 : 329 - 360
  • [67] Ehrlich P., 1909, NED TIJDSCHR GENEES, V5, P273, DOI DOI 10.1101/833004
  • [68] Elder GJ, 1997, CLIN TRANSPLANT, V11, P565
  • [69] Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression
    Engel, AM
    Svane, IM
    Mouritsen, S
    Rygaard, J
    Clausen, J
    Werdelin, O
    [J]. APMIS, 1996, 104 (09) : 629 - 639
  • [70] Deficiencies of GM-CSF and interferon γ link inflammation and cancer
    Enzler, T
    Gillessen, S
    Manis, JP
    Ferguson, D
    Fleming, J
    Alt, FW
    Mihm, M
    Dranoff, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (09) : 1213 - 1219